News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
338,360 Results
Type
Article (20455)
Company Profile (129)
Press Release (317775)
Multimedia
Podcasts (88)
Webinars (15)
Section
Business (105673)
Career Advice (885)
Deals (18594)
Drug Delivery (98)
Drug Development (50923)
Employer Resources (80)
FDA (7752)
Job Trends (7796)
News (186426)
Policy (17406)
Tag
Academia (738)
Accelerated approval (8)
Adcomms (21)
Allergies (53)
Alliances (27989)
ALS (65)
Alzheimer's disease (698)
Antibody-drug conjugate (ADC) (119)
Approvals (7788)
Artificial intelligence (191)
Autoimmune disease (24)
Automation (8)
Bankruptcy (178)
Best Places to Work (5564)
BIOSECURE Act (13)
Biosimilars (115)
Biotechnology (57)
Bladder cancer (50)
Brain cancer (25)
Breast cancer (156)
Cancer (1491)
Cardiovascular disease (145)
Career advice (721)
Career pathing (21)
CAR-T (70)
CDC (8)
Cell therapy (190)
Cervical cancer (8)
Clinical research (43422)
Collaboration (628)
Compensation (242)
Complete response letters (29)
COVID-19 (1120)
CRISPR (35)
C-suite (248)
Cystic fibrosis (69)
Data (1739)
Decentralized trials (2)
Denatured (23)
Depression (41)
Diabetes (181)
Diagnostics (1838)
Digital health (7)
Diversity (7)
Diversity, equity & inclusion (23)
Drug discovery (103)
Drug pricing (138)
Drug shortages (33)
Duchenne muscular dystrophy (90)
Earnings (39807)
Editorial (35)
Employer branding (10)
Employer resources (76)
Events (49505)
Executive appointments (557)
FDA (8671)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (2)
Funding (431)
Gene editing (64)
Generative AI (19)
Gene therapy (187)
GLP-1 (677)
Government (1918)
Grass and pollen (4)
Guidances (121)
Healthcare (5917)
HIV (19)
Huntington's disease (16)
IgA nephropathy (32)
Immunology and inflammation (118)
Immuno-oncology (11)
Indications (27)
Infectious disease (1215)
Inflammatory bowel disease (94)
Inflation Reduction Act (10)
Influenza (29)
Intellectual property (79)
Interviews (116)
IPO (7405)
IRA (50)
Job creations (2442)
Job search strategy (651)
Kidney cancer (8)
Labor market (40)
Layoffs (308)
Leadership (18)
Legal (4135)
Liver cancer (33)
Longevity (6)
Lung cancer (224)
Lymphoma (130)
Machine learning (6)
Management (30)
Manufacturing (303)
MASH (66)
Medical device (1986)
Medtech (1989)
Mergers & acquisitions (11540)
Metabolic disorders (620)
Multiple sclerosis (63)
NASH (20)
Neurodegenerative disease (72)
Neuropsychiatric disorders (30)
Neuroscience (1120)
NextGen: Class of 2025 (2363)
Non-profit (914)
Now hiring (32)
Obesity (375)
Opinion (206)
Ovarian cancer (45)
Pain (95)
Pancreatic cancer (63)
Parkinson's disease (100)
Partnered (11)
Patents (193)
Patient recruitment (88)
Peanut (18)
People (33882)
Pharmaceutical (74)
Pharmacy benefit managers (25)
Phase I (13621)
Phase II (18348)
Phase III (14747)
Pipeline (1082)
Policy (177)
Postmarket research (1621)
Preclinical (4784)
Press Release (29)
Prostate cancer (89)
Psychedelics (19)
Radiopharmaceuticals (168)
Rare diseases (309)
Real estate (3185)
Recruiting (30)
Regulatory (12868)
Reports (24)
Research institute (824)
Resumes & cover letters (139)
Rett syndrome (1)
RNA editing (6)
RSV (31)
Schizophrenia (78)
Series A (80)
Series B (47)
Service/supplier (7)
Sickle cell disease (42)
Special edition (17)
Spinal muscular atrophy (112)
Sponsored (15)
Startups (2024)
State (2)
Stomach cancer (10)
Supply chain (60)
Tariffs (67)
The Weekly (63)
Vaccines (321)
Venture capital (41)
Weight loss (265)
Women's health (18)
Worklife (8)
Date
Today (59)
Last 7 days (260)
Last 30 days (952)
Last 365 days (15841)
2025 (9399)
2024 (17686)
2023 (19656)
2022 (25886)
2021 (26675)
2020 (24903)
2019 (20082)
2018 (15621)
2017 (17271)
2016 (16203)
2015 (18807)
2014 (14788)
2013 (12552)
2012 (13483)
2011 (13818)
2010 (12738)
Location
Africa (412)
Alabama (29)
Alaska (1)
Arizona (72)
Arkansas (8)
Asia (25282)
Australia (3260)
California (3323)
Canada (1378)
China (473)
Colorado (127)
Connecticut (128)
Delaware (109)
Europe (52225)
Florida (594)
Georgia (73)
Hawaii (1)
Idaho (17)
Illinois (328)
India (23)
Indiana (212)
Iowa (3)
Japan (184)
Kansas (69)
Kentucky (24)
Louisiana (3)
Maine (4)
Maryland (456)
Massachusetts (2799)
Michigan (54)
Minnesota (174)
Mississippi (3)
Missouri (31)
Montana (10)
Nebraska (11)
Nevada (25)
New Hampshire (8)
New Jersey (1341)
New Mexico (21)
New York (967)
North Carolina (599)
North Dakota (2)
Northern California (1415)
Ohio (96)
Oklahoma (6)
Oregon (22)
Pennsylvania (773)
Puerto Rico (15)
Rhode Island (19)
South America (610)
South Carolina (6)
Southern California (1378)
Tennessee (48)
Texas (450)
United States (13123)
Utah (71)
Virginia (123)
Washington D.C. (53)
Washington State (265)
West Virginia (1)
Wisconsin (32)
338,360 Results for "kite pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites
Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.
November 15, 2024
·
2 min read
·
Angela Gabriel
Job Trends
Amidst Industry Challenges, 85% of Pharmas Increase Investment in AI
A new report found that 85% of pharma respondents are increasing their artificial intelligence investments, and 70% see AI as an immediate priority. Two experts discuss how biopharmas are implementing and adopting AI, including their increased use of external help with the process.
July 31, 2025
·
4 min read
·
Angela Gabriel
Earnings
AstraZeneca CEO Says World ‘Needs to Share’ in Global Pharma R&D
Pascal Soriot’s comments came during AstraZeneca’s Q2 earnings call in regard to President Donald Trump’s newly announced European pharma tariffs. The company also announced estimate-beating earnings, with its cancer portfolio driving earnings despite clinical roadblocks.
July 29, 2025
·
3 min read
·
Tristan Manalac
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Deals
Revolution Establishes Endless Cash Runway With $2B Royalty Pharma Deal
In May, Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.
June 24, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
June 2, 2025
·
17 min read
Business
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform
Cellares today announced that Kite , a Gilead Company, will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle.
June 27, 2024
·
2 min read
Clinical research
Undeterred by Political, Economic Headwinds, Pharma Ups R&D Investment in 2024 and Beyond
R&D spending across the global pharmaceutical sector climbed 1.5% in 2024, according to unreleased data from Evaluate Pharma.
May 28, 2025
·
12 min read
·
Tristan Manalac
Business
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabtagene ciloleucel) is well-tolerated in patients living with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL).
June 3, 2024
·
19 min read
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
1 of 33,836
Next
